Search results
Results From The WOW.Com Content Network
Purpose-built with a focus on acute and pressing needs in rare and gynecologic cancers, we unite science, technology and talent to get ahead of disease together. At GSK Oncology, we are leading the way to re-imagine improved ways of engaging with people with cancer and their loved ones.
GSK plc (LSE/NYSE: GSK) today announced that findings across its oncology portfolio will be presented in 25 abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (31 May - 4 June) in Chicago, IL.
Join us in Oncology to help improve the lives of patients around the world. We offer global career opportunities across all areas of drug development and commercialization. Search our global career finder to see all vacancies in this area.
The field of immuno-Oncology (I-O) was revolutionised with the discovery of T-cell immune checkpoints CTLA-4 and PD-1. Blocking these brought about a number of autoimmune adverse events, but with it an enhanced immune response against tumours.
GSK has a diverse portfolio and pipeline, including three marketed oncology medicines and 16 assets in clinical development that leverage the science of the immune system, human genetics and advanced technologies to address a variety of tumour types.
GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Sierra Oncology, Inc. (Sierra Oncology), a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer.
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR ...
At GSK, our goal is to enable the immune system to target and potentially offer a cure for all types of cancer through personalized approaches to treatment. This is why we are exploring the potential of the CD226 axis, a promising new target for the next generation of immuno-oncology therapies.
Our specialty medicines is focused on four therapeutic areas: infectious diseases, HIV, respiratory/immunology and oncology. We’re leaders in infectious diseases and HIV innovation and we’re building our positions in immunology and oncology.
GSK, a leader in oncology R&D, has advanced its innovative pipeline by focusing on science related to the immune system, the use of human genetics and cutting-edge technologies that will advance the next wave of cancer therapies with the potential to transform outcomes for patients.